
|Videos|July 24, 2014
Observation Versus Treatment in Men with Prostate Cancer
Author(s)Peter Yu, MD
Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men’s treatment decisions after seeing a rise in their PSA levels. <
Advertisement
Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men’s treatment decisions after seeing a rise in their PSA levels.
Clinical Pearls:
- One of the studies presented at the 2014 ASCO Annual Meeting reviewed data of men who decided to wait or pursue treatment.
- Results of this study showed there was no difference in survival regardless of their decision.
- Men and doctors can now better discuss remaining on observation or starting treatment.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
Early Relapse Guides Use of CAR T vs Other Options in LBCL
3
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5









































